Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Immuno-oncology biotech Five Prime has outlicensed a medication from its protein discovery platform exclusively to Belgium biopharma UCB.
The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
Norbert Bischofberger is stepping down as Gilead's EVP of R&D and chief scientific officer, as the company promotes John McHutchison to the top job.
Anthera has cut loose its failed late-stage Lilly castoff Sollpura as it seeks “strategic alternatives.”
The French pharma’s decision gives Alnylam control of a phase 3-ready rare disease drug with an FDA breakthrough therapy designation.
As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug.
Pfizer is backing out of its $635 million armed antibody tech deal with CytomX.
A CAR-T biotech formed by Juno and WuXi got off a $90 million series A with Chinese backing, as it eyes clinical trials of its new cancer therapy.
Sanofi will license out a host of infectious disease assets to Evotec, with 100 staffers also moving into its R&D engine.